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Abstract 
Background 
The ventricular ectopic QRS interval (VEQSI) has been shown to identify 
structural heart disease and predict mortality. In arrhythmogenic right ventricular 
cardiomyopathy (ARVC) early diagnosis is difficult with current methods and life-
threatening arrhythmias are common and difficult to predict.  
Objectives 
To assess the utility of ventricular ectopic indices including VEQSI in ARVC 
diagnosis. 
Methods 
We studied 70 patients with ARVC; 30 with definite disease (47±12 years; 60% 
male); 40 with incomplete disease expression (44±18 years; 44% male); 116 
healthy controls (40±15 years; 56% male); and 26 patients with normal heart 
right ventricular outflow tract (RVOT) ectopy (46±17 years; 27% male). The 
duration of the broadest ventricular ectopic beat during 12-lead Holter monitoring 
was recorded as VEQSI max. 
Results 
VEQSI max was associated with age and gender, not conducted QRS duration. 
Adjusted VEQSI max was greater in ARVC patients than control groups. In 
healthy males (44.5 years) estimated VEQSI max was 163ms (95%CI 159ms-
167ms); in definite ARVC 212ms (95%CI 206ms-217ms); in incompletely 
expressed ARVC 204ms (95%CI 199ms-210ms); and in normal heart RVOT 
ectopy 171ms (95%CI 165ms-178ms). VEQSI max >180ms had 98% sensitivity 
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and specificity for the diagnosis of ARVC (AUC 0.99; 95%CI 0.980-0.998). In our 
incompletely expressed ARVC patients, VEQSI max >180ms identified 88% as 
affected. 
Conclusion 
VEQSI max distinguishes ARVC patients, including those with incomplete 
disease expression, from healthy controls and patients with normal heart RVOT 
ectopy. 
 
Keywords 
arrhythmogenic right ventricular cardiomyopathy; implantable cardioverter-
defibrillator; sudden cardiac death; ventricular ectopic QRS interval (VEQSI); 
ventricular ectopic beat  
 
 5 
Introduction 
With intact cardiac conduction the QRS may remain narrow in the presence of 
abnormal ventricular myocardium. Ventricular ectopic beats (VEB) are usually 
conducted through the myocardium with limited participation of specialized 
conduction tissue, so the QRS interval of VEB may provide an index of 
myocardial condition and risk of sudden cardiac death (SCD).(1) We have 
previously demonstrated that the ventricular ectopic QRS interval (VEQSI) is 
associated with mortality in an unselected population.(2) In ischaemic heart 
disease, VEB duration and complexity has been shown to correlate with left 
ventricular (LV) dilatation and dysfunction.(3)  
 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) manifests with an initial 
concealed phase in which ventricular arrhythmia can occur, but ventricular 
structure and function is preserved. There is no single diagnostic test for ARVC; 
diagnosis relies on meeting Task Force criteria.(4) Electrocardiographic capture 
of ventricular tachycardia (VT) with left bundle branch block (LBBB) superior axis 
is the sole major arrhythmia criterion, but a minority of affected patients exhibit 
VT at any given assessment and some never develop VT.  
 
ARVC shares common features with normal heart right ventricular outflow tract 
(RVOT) ectopy: both affect young people and are associated with LBBB 
morphology ventricular arrhythmia, frequently precipitated by exercise. 
Differentiation between conditions is important to guide therapy and follow-up 
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and assess SCD risk. Whereas RVOT ectopy appears benign, ARVC is 
associated with risk of SCD.(5, 6)  
 
During the concealed phase, ARVC diagnosis is difficult due to diffuse structural 
abnormalities. Imaging demonstrates normal cardiac appearance or subtle non-
diagnostic anomalies. Electrical changes appear to predate structural changes 
and VEB are frequent.(7,8) We hypothesized that VEB indices: VEQSI, number 
of VEB morphologies and VEB fragmentation would provide markers for 
presence and severity of abnormal ventricular structure and function and a 
measure of the risk of ventricular arrhythmia.(1) We hypothesized that VEB 
indices may be useful in early ARVC diagnosis. 
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Methods 
Patient characteristics 
ARVC patients were identified from databases at St George’s Hospital London, 
the Heart Hospital London and the University of Bologna. Their clinical data were 
analysed for contemporaneous disease categorization by Task Force criteria 
(supplementary table 1).(4) 30 patients (4712 years; 60% male) with definite 
disease were recruited. Amongst this group, 17 had prior life-threatening 
arrhythmia (cardiac arrest and/or sustained VT resulting in haemodynamic 
collapse). 40 patients (4418 years; 43% male) with incompletely expressed 
ARVC were recruited. These patients had borderline clinical phenotype 
consisting of one minor Task Force criterion, non-diagnostic cardiac imaging and 
definite ARVC confirmed in a first-degree relative using Task Force criteria 
and/or at post-mortem. None was symptomatic (table 1). 
 
ARVC patients were compared with 116 normal controls (40±15 years; 56% 
male). These were individuals without cardiac disease or risk factors, family 
history of inherited heart disease or significant abnormality on electrocardiogram 
(ECG) and echocardiography. A second control group was recruited with 26 
patients under follow-up/pre-ablation for RVOT ectopy (4617 years; 27% male) 
who also had normal ECGs and echocardiograms (table 1). 
 
LV involvement was defined as ejection fraction 50% and/or late enhancement 
on cardiac magnetic resonance imaging (CMR). Informed consent was obtained 
 8 
from each patient. The study received local ethics committee approval and 
complied with the Declaration of Helsinki.  
 
Electrocardiography 
Digital 10-second 12-lead ECGs were acquired (Cardiosoft™ GE Healthcare, UK) 
and reviewed at 10mm/mV and 25mm/s. PR, RR, QRS and QT intervals were 
recorded. The QT-interval was corrected (QTc) using Bazett’s formula. Presence 
of epsilon waves and T-wave inversion in leads V1-V6 and II, III and aVF was 
noted. 
 
Holter monitoring 
Holter monitoring was performed for 24hours. Digital 10-electrode 12-channel 
devices with sampling frequency of 1024Hz (CardioMem® CM3000-12, Getemed, 
Germany) were applied in the Mason-Likar configuration. Analysis was 
performed on a commercial workstation (Cardioday®, Getemed, Germany). All 
recordings were analysed by the same physician, blinded to the clinical 
diagnosis, who performed manual over-reading to eliminate artifact and correct 
the automated identification of VEBs and classification by morphology. The 
following Holter variables were evaluated: minimum, mean and maximum heart 
rate; VEB presence, frequency, site of origin; VT presence, frequency, site of 
origin. Definitions included: VT ≥3 consecutive VEB; frequent VEB >500/24hours. 
VEB and VT types/origins were classified according to Task Force criteria: LBBB 
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superior axis, LBBB inferior axis, right-bundle branch block (RBBB) superior axis 
or RBBB inferior axis.(4)  
 
Three novel VEB indices were examined: VEQSI, number of VEB morphologies 
and VEB fragmentation. All VEBs in each recording were inspected. Differences 
in VEB morphology were identified with reference to bundle branch block pattern, 
QRS axis and R-wave progression.(9) Fusion beats, couplets and VT were 
excluded from VEB analysis. The number of VEB morphologies was counted and 
recorded. VEQSI and VEB fragmentation were measured for each VEB 
morphology from a representative QRS complex, chosen for the clarity of onset 
and termination (figure 1).  
 
VEQSI measurements were made using electronic calipers on a simultaneous 
12-derivation ECG segment (20mm/mV, 100mm/s) from the start of the QRS 
showing the earliest onset to the end of the QRS showing the latest termination 
across all leads. The duration of the broadest VEB was VEQSI max.(2) 
Fragmentation measurements were made on a simultaneous 12-derivation ECG 
segment (10mm/mV, 25mm/s). VEB fragmentation was defined as >2 notches in 
the R’ or S waves and/or 2 notches separated by >40ms.(10) The maximum 
number of fragmented leads was fragmentation max.  
 
Inter-observer and intra-observer variability were measured using a subset of 22 
Holter recordings analysed blindly by three different observers and on two 
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occasions by one observer. Inter-observer variability intraclass correlation 
coefficients (ICC) were 0.93 for VEQSI max, 0.90 for VEB morphologies and 0.90 
for VEB fragmentation max. Intra-observer variability ICC were 0.97 for VEQSI 
max, 0.99 for VEB morphologies and 0.95 for VEB fragmentation max. 
 
Statistical analysis 
Statistical tests were performed using STATA (StataCorp. 2011 Stata Statistical 
Software:Release 12. College Station, TX:StataCorp LP.) and R (http://www.R-
project.org/). Summary statistics were presented: means, medians, standard 
deviations (SD), inter-quartile ranges (IQR) for continuous variables and 
proportions for categorical variables. The Shapiro–Wilk test was used to assess 
normality of data. 
 
Univariate and multivariable analyses were performed to investigate the 
relationship between VEB indices: VEQSI max, number of VEB morphologies 
and VEB fragmentation max with age, gender, conducted QRS duration and 
disease group. For these analyses, only patients with VEB could be included. A 
parsimonious model was derived. Techniques included forward regression, 
backward elimination and a combination of both. An alpha-level of <0.05 was 
considered significant. Potential interaction effects were considered, kept in the 
model if statistically or clinically significant and interpreted accordingly. Residual 
plots were used to assess adequacy of the models and assumptions. Predictions 
stratified by age, gender and disease group were presented. 
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VEB morphologies were categorized as follows: 1=1-2 morphologies (64%); 2=3 
morphologies (10%); 3=≥4 morphologies (26%). VEB fragmentation was 
categorized as follows: 1=fragmentation max 1-2 (53%); 2=fragmentation max 3-
4 (19%); 3=fragmentation max 5-6 (26%); 4=fragmentation max ≥7 (17%). 
Associations with other variables were expressed in terms of proportional odds 
for those in groups >k versus those in groups ≤k, where k is the level of the 
response variable defined above. 
 
Receiver operating characteristic (ROC) curve analysis was used to examine the 
extent to which VEB indices can be used as markers of disease and establish 
diagnostic ranges. ARVC patients were compared with normal controls and 
RVOT ectopy patients. Accuracy was measured by area under the curve (AUC) 
and the corresponding results were compared. Thresholds for optimum 
sensitivity and specificity of each VEB index were derived, with results adjusted 
for age and gender.  
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Results 
Holter characteristics 
VEB were present in the majority of subjects (table 1). In normal controls the 
commonest VEB morphology was RBBB superior axis suggesting an LV origin. 
In ARVC the commonest VEB morphology was LBBB superior axis and in RVOT 
ectopy the commonest VEB morphology was LBBB inferior axis, suggesting right 
ventricular (RV) origins. 
 
VT occurred in 30% definite ARVC, 15% incompletely expressed ARVC and 8% 
RVOT ectopy patients. In definite ARVC the commonest VT morphologies were 
LBBB inferior and LBBB superior axis (44% patients with VT). In incompletely 
expressed ARVC the commonest VT morphology was LBBB superior axis (67% 
patients with VT). In RVOT ectopy all VT was LBBB inferior axis.  
 
VEQSI max 
VEQSI max was longer in definite and incompletely expressed ARVC patients 
than normal controls and RVOT ectopy patients (209±18ms, 200±12ms, 
159±16ms and 165±14ms respectively; table 1; figure 2; raw data). 
 
VEQSI max was associated with age and gender, not conducted QRS duration 
(table 2). Adjusted VEQSI max remained greater in ARVC patients than control 
groups. In healthy males (average age 44.5 years) estimated VEQSI max was 
163ms (95%CI 159ms-167ms); in definite ARVC 212ms (95%CI 206ms-217ms); 
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in incompletely expressed ARVC 204ms (95%CI 199ms-210ms); and in RVOT 
ectopy 171ms (95%CI 165ms-178ms; supplementary table 2). 
 
VEB morphologies 
There were more VEB morphologies in definite and incompletely expressed 
ARVC patients than normal controls and RVOT ectopy patients (5±4, 3±4, 1±1 
and 2±1 respectively; table 1; raw data). 
 
The number of VEB morphologies was associated with age and gender, not 
conducted QRS duration (table 2). Adjusted VEB morphologies remained greater 
in ARVC patients than control groups. In incomplete ARVC the odds of ≥4 (vs <4) 
VEB morphologies was 11.1 times greater than in normal controls and 2.6 times 
greater than in RVOT ectopy patients. 
 
VEB fragmentation max 
VEB fragmentation max was greater in definite and incompletely expressed 
ARVC patients than normal controls and RVOT ectopy patients (7±3, 3±4, 1±3 
and 2±3 respectively; table 1; raw data). 
 
VEB fragmentation max was associated with age, not gender or conducted QRS 
duration (table 2). Adjusted VEB fragmentation max remained greater in ARVC 
patients than control groups. In incomplete ARVC the odds of VEB fragmentation 
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max ≥7 (vs <7) was 3.0 times greater than in normal controls and 1.2 times 
greater than in RVOT ectopy patients. 
 
Diagnosis of incompletely expressed ARVC using novel VEB indices 
VEQSI max was the strongest VEB index for ARVC diagnosis (AUC 0.993; 
95%CI 0.980-0.998; table 3; supplementary figure). Although VEB number, 
VEQSI max, VEB morphologies and VEB fragmentation max were all univariate 
markers of disease, following multivariable analysis only VEQSI max remained 
significant (OR 2.35; 95%CI 1.30-4.25; p=0.005; supplementary table 3). VEQSI 
max effectively differentiated incompletely expressed ARVC patients from normal 
controls (41.76; 95%CI 35.51-48.46; p<0.001) and RVOT ectopy patients (33.14; 
95% CI 25.73-40.55; p<0.001; table 2). With an optimum threshold of >180ms 
VEQSI max had 98% sensitivity and specificity for ARVC diagnosis (table 3). 
 
Comparison with Task Force criteria  
VEQSI max >180ms identified 100% definite ARVC patients whereas major Task 
Force criteria for arrhythmias were met in 13-23% and minor criteria in 53-73% 
patients (supplementary table 4). VEQSI max >180ms identified 88% 
incompletely expressed ARVC patients whereas major Task Force criteria for 
arrhythmias were met in 10% and minor criteria in 38-45% patients. VEQSI max 
excluded 85% of RVOT ectopy patients whereas minor ARVC Task Force criteria 
for arrhythmias were met in 58% patients. 
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Prediction of events 
VEQSI max was longer in ARVC patients with previous life-threatening 
arrhythmia than in those without (21718ms and 19911ms; supplementary table 
5; raw data). Univariate analysis identified potential markers of prior life-
threatening events but after multivariable analysis only unexplained syncope and 
VEQSI max remained significant (table 4). VEQSI max was the strongest 
predictor with a 1ms increase in VEQSI max increasing the odds of previous life-
threatening arrhythmia by a factor of 1.1 (95%CI 1.03-1.15; p=0.001). 
 
VEQSI max and RV structural changes  
In patients with normal RV size, VEQSI max was longer in those with definite and 
incompletely expressed ARVC compared with normal controls and RVOT ectopy 
patients (20215ms, 20012ms, 15916ms and 16514ms respectively). In 
RVOT origin VEB, VEQSI was longer in patients with definite and incompletely 
expressed ARVC compared with normal controls and RVOT ectopy patients 
(LBBB inferior axis VEB 18425ms, 19118ms, 15915ms and 16114ms 
respectively; figure 3). 
 
Antiarrhythmic drugs 
Nine ARVC patients received sotalol therapy which can influence conduction. 
Following exclusion of these patients, VEQSI max remained longer in definite 
and incompletely expressed ARVC patients compared with normal controls and 
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RVOT ectopy patients (206±18ms, 200±12ms, 161±15ms and 165±14ms 
respectively).  
 
Discussion 
VEB indices: VEQSI max, number of VEB morphologies and VEB fragmentation 
max distinguished patients with definite and incompletely expressed ARVC from 
normal controls and patients with normal heart RVOT ectopy. VEQSI max was 
the strongest index. VEQSI max >180ms had high sensitivity and specificity for 
the identification of ARVC, making it a potentially useful diagnostic test. Moreover 
VEQSI max >180ms increased the diagnostic yield in ARVC patients compared 
with Task Force criteria for arrhythmias. 
 
Diagnosis of incompletely expressed ARVC 
There is no gold standard investigation for ARVC; diagnosis relies on meeting 
Task Force criteria. First-degree relatives of a proband are frequently referred for 
screening without signs or symptoms and there is phenotypic heterogeneity.(11–
13) Early ARVC may go unrecognized or be confused with RVOT ectopy.  
 
Our incompletely expressed ARVC patients had an affected first-degree relative, 
one minor Task Force criterion, non-diagnostic cardiac imaging and insufficient 
phenotype to fulfil definite criteria. These are patients where diagnosis is most 
challenging. ARVC identification and differentiation from RVOT ectopy is 
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important to guide therapy and follow-up and assess SCD risk. Whereas RVOT 
ectopy appears benign, ARVC is associated with risk of SCD.(5,6)  
 
In early ARVC, cardiac imaging is frequently normal and electrical changes 
appear to predate structural changes.(4,7,8) Despite a perception that innocent 
ventricular arrhythmia arises in the RVOT, it is common to observe outflow tract 
arrhythmia in ARVC.(4) Both of these factors can make early diagnosis difficult.  
 
In our incompletely expressed ARVC patients, 100% had normal RV size and 
function and 35% VEB originated in the RVOT. Major and minor ARVC Task 
Force arrhythmia criteria were demonstrated in only 10% and 45% of these 
patients respectively, but VEQSI max >180ms identified 88% as affected. In 
addition, VEQSI max >180ms was found in only 15% RVOT ectopy patients 
whereas minor Task Force criteria identified 58% RVOT ectopy patients as 
potential carriers of ARVC.  
 
Multivariable analysis demonstrated that VEQSI max was a stronger marker for 
ARVC diagnosis compared with other VEB indices. VEQSI max had the highest 
sensitivity and specificity and we propose it as the most useful index. Automated 
measurement of VEQSI max is likely to be most robust and we have shown that 
Holter monitoring with fewer leads is sufficient.(2)   
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Comparison with other studies 
Longer QRS duration in definite ARVC patients compared with RVOT ectopy 
patients has been demonstrated during VT.(14,15) QRS duration 120ms (lead I) 
from paper ECGs had 88-100% sensitivity and 46-48% specificity for ARVC 
diagnosis. Addition of other parameters (QRS axis, notching, precordial transition 
during VT and T-wave inversion in leads V1+V2 on the resting ECG) improved 
specificity to 100%.(14,15) VEQSI max, however, demonstrates similar sensitivity 
and specificity as an isolated index and is useful for the diagnosis of incompletely 
expressed ARVC as well as definite disease.  
 
VEQSI measurement only requires presence of VEB making it applicable for a 
greater number of patients. In our cohorts 30% definite ARVC, 15% incompletely 
expressed ARVC and 8% RVOT ectopy patients exhibited VT, whereas 100% 
definite ARVC and RVOT ectopy patients and 90% incompletely expressed 
ARVC patients demonstrated VEB. The VEQSI max diagnostic cut-off was longer 
than QRS duration measured during VT on paper ECGs.(14,15) However, 
VEQSI max was measured from the earliest VEB onset to the latest termination 
across all ECG leads whereas in previous studies QRS measurements were 
made for each individual lead. In addition, digital recording with high 
magnification measurement of an isolated VEB allows more accurate 
determination of VEB onset and termination than during VT on paper ECGs 
where low magnification measurements are more challenging and VEB onset 
and termination may be obscured by successive beats. 
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Risk stratification 
ARVC risk stratification is challenging and SCD is the first presentation in up to 
50% of individuals.(5,13) Death frequently occurs during the concealed phase. 
Aborted SCD, VT causing hemodynamic compromise and unexplained syncope 
are risk factors for subsequent events and warrant implantable cardioverter-
defibrillator therapy. Less well established risk factors include left ventricular 
involvement and family history of SCD.(16–18) In our ARVC patients, VEQSI 
max was longer in those with previous life-threatening arrhythmia compared with 
asymptomatic subjects. Multivariable analysis established that unexplained 
syncope and VEQSI max were independent markers of prior life-threatening 
events and VEQSI max was the strongest. VEQSI max may be a predictor of 
arrhythmic events, but prospective follow-up with survival analysis is necessary 
to confirm this. 
 
VEQSI max 
Ventricular arrhythmias arising near the septum have shorter QRS duration than 
those arising in the free wall due to more proximal activation of the His-Purkinje 
system and simultaneous LV/RV activation.(19) Longer VEQSI max in ARVC 
patients could result from VEB originating in the RV free wall, causing 
lengthening of the conduction pathway compared with VEB arising near the 
septum in normal controls and RVOT ectopy patients. However, when RVOT 
origin VEB were considered in isolation, VEQSI max remained longer in ARVC 
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patients than controls. In addition when patients with RV dilatation were 
excluded, VEQSI max remained longer in ARVC patients compared with 
controls. Myocardial VEB velocity appears slower in ARVC even in the absence 
of overt structural anomalies. Indeed invasive electrophysiological mapping of 
genetically proven ARVC patients without overt structural disease demonstrated 
conduction slowing compared with controls.(7) This was supported by 
histopathological mis-localisation of gap junction proteins. In addition, in 
idiopathic ventricular arrhythmia patients, broader QRS duration has been 
associated with myocardial scar.(20) 
 
Conclusion 
VEQSI max, number of VEB morphologies and VEB fragmentation max 
distinguish ARVC patients, including those with incomplete disease expression, 
from healthy controls and RVOT ectopy patients. VEQSI max is the strongest 
diagnostic marker. We propose VEQSI max as a promising clinical index for 
ARVC diagnosis and risk stratification. 
 
Study Limitations 
ARVC is a rare disease and the sample size is relatively small. In rare diseases 
sensitivity and specificity tests result in high values and ROC curve analysis has 
lower accuracy. The interpretation of results should be considered in this context. 
Prospective validation of these phenotyping parameters was not possible which 
represents a major study limitation. 
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Tables 
Table 1 Data from normal controls, right ventricular outflow tract (RVOT) ectopy 
patients and patients with definite and incompletely expressed arrhythmogenic 
right ventricular cardiomyopathy (ARVC). 
 
 
Definite 
ARVC 
(n=30) 
Normal  
controls  
(n=116) 
Normal heart 
RVOT  
ectopy  
(n=26) 
Incompletely 
expressed 
ARVC 
(n=40) 
Age (years) 4712 4015 4617 4418 
Gender (male;%) 60 56 27 43 
Medications (%) 
 Beta-blocker 
 Sotalol 
 Other 
 
70 
20 
20 
 
0 
0 
0 
 
27 
0 
19 
 
25 
8 
0 
Pathogenic mutation (%) 47 NA NA 55 
Right ventricular dilatation (%) 
 Normal 
 Mild  
 Moderate/severe 
 
47 
37 
17 
 
100 
0 
0 
 
100 
0 
0 
 
100 
0 
0 
Right ventricular impairment (%) 
 Normal 
 Mild 
 Moderate/severe 
 
50 
33 
17 
 
100 
0 
0 
 
100 
0 
0 
 
100 
0 
0 
Left ventricular involvement (%) 23 0 0 13 
T-wave inversion V1+V2 (%) 70 1 12 8 
T-wave inversion beyond V2 (%) 57 0 0 0 
Epsilon wave (%) 10 0 0 0 
Abnormal SAECG (%) 58 NA NA 48 
Prior frequent VEB>500/24 hours (%) 33 NA NA 43 
Prior VT LBBB superior axis (%) 23 NA NA 0 
Prior VT LBBB other axis (%) 57 NA NA 3 
Subjects with VEB (%) 100 57 100 90 
VEB/24 hours (n;medianIQR) 
VEB morphology (%) 
 LBBB superior 
 LBBB inferior 
 RBBB superior 
 RBBB inferior 
4161423 
 
41 
31 
23 
5 
38 
 
32 
25 
36 
7 
10033877 
 
21 
61 
14 
4 
2671083 
 
36 
35 
21 
8 
Frequent VEB>500/24 hours (%) 47 1 54 38 
Subjects with VT (%) 30 0 8 15 
VT LBBB superior axis (%) 13 0 0 10 
VT other axis (%) 17 0 8 5 
VEQSI max (ms;meanSD) 20918 15916 16514 20012 
VEB morphologies (n;medianIQR) 54 11 21 34 
VEB fragmentation max (n;medianIQR) 73 13 13 34 
 
VEB, ventricular ectopic beat; VT, ventricular tachycardia; VEQSI, ventricular 
ectopic QRS interval  
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Table 2 Univariate and multivariable analyses of the ventricular ectopic beat 
(VEB) indices adjusted for age, gender and conducted QRS duration. 
 
Univariate analysis Final model 
VEQSI max  Estimate p-value 95%CI Estimate p-value 95%CI 
Age (5-year effect) 1.37 0.038 0.02,0.53 1.91 0.001 0.80,3.03 
Gender -6.90 -.102 -15.18,1.38 -7.97 0.001 -12.77,-3.16 
Conducted QRS  0.35 0.019 0.06,0.64    
D-ARVC vs. NC†  49.93 <0.0001 43.28,56.59 49.05 <0.001 42.70,55.40 
D-ARVC vs. RVOT*     40.43 <0.001 32.56,48.29 
IE-ARVC vs. NC† 40.89 <0.0001 34.62,47.15 41.76 <0.001 35.51,48.46 
IE-ARVC vs. RVOT*     33.14 <0.001 25.73,40.55 
VEB morphologies  OR p-value 95%CI OR p-value 95%CI 
Age (5-year effect) 1.19 0.001 1.07,1.33 1.26 <0.001 1.11,1.44 
Gender 0.52 0.049 0.27,0.99 0.42 0.039 0.18,0.96 
Conducted QRS 1.02 0.006 0.99,1.05    
D-ARVC vs. NC 26.00 <0.001 9.16,73.82 31.4 <0.001 10.27,96.07 
D-ARVC vs. RVOT  3.48 <0.001 2.05,4.90 3.67 <0.001 2.15,5.20 
IE-ARVC vs. NC 7.84 <0.001 3.03,20.27 11.13 <0.001 3.93,31.55 
IE-ARVC vs. RVOT  2.28 0.001 0.92,3.64 2.63 <0.001 1.16,4.10 
VEB fragmentation max OR p-value 95%CI OR p-value 95%CI 
Age (5-year effect) 1.03 0.001 1.01,1.05 1.22 <0.001 1.10,1.36 
Gender 0.51 0.032 0.28,0.94    
Conducted QRS 1.03 0.024 1.00,1.04    
D-ARVC vs. NC 27.95 <0.001 10.57,73.93 30.37 <0.0001 11.24,82.07 
D-ARVC vs. RVOT  3.31 <0.001 2.15,4.46 3.5 <0.0001 2.30,4.70 
IE-ARVC vs. NC 2.72 <0.015 1.22,6.08 2.98 <0.0001 1.30,6.84 
IE-ARVC vs. RVOT  0.97 0.061 -0.05,1.99 1.19 0.028 0.13,2.26 
 
†Final model with NC as baseline cohort 
*Final model with RVOT ectopy as baseline cohort 
D-ARVC, definite arrhythmogenic right ventricular cardiomyopathy; IE-ARVC, 
incompletely expressed ARVC; NC, normal controls; RVOT, right ventricular 
outflow tract ectopy; VEQSI, ventricular ectopic QRS interval; OR, odds ratio; CI, 
confidence interval  
 26 
Table 3 Sensitivity and specificity of the ventricular ectopic beat (VEB) indices in 
arrhythmogenic right ventricular cardiomyopathy diagnosis. 
 
 
AUC 95%CI AUC difference 
AUC 
difference 
95%CI p-value Threshold Sensitivity Specificity 
 
VEQSI max(ms)  
 
0.993 (0.980,0.998) - - - - 180 0.98 0.98 
 
VEB morphologies(n) 
 
0.845 (0.772,0.908) 
VEQSI max vs. VEB 
morphologies 
-0.148 (-0.219,-0.088) <0.0001 2 0.76 0.75 
 
VEB fragmentation 
max(n) 
 
0.819 (0.739,0.879) 
VEQSI max vs. VEB 
fragmentation max 
-0.174 (-0.249,-0.112) <0.0001 2 0.71 0.71 
   
VEB morphologies vs.  
VEB fragmentation max 
-0.026 (-0.087,0.025) 0.37    
 
VEQSI, ventricular ectopic QRS interval; AUC, area under the curve; CI, 
confidence interval 
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Table 4 Univariate and multivariable analyses of markers for prior life-threatening 
arrhythmia in arrhythmogenic right ventricular cardiomyopathy patients. 
 
 Univariate Analysis Multivariable Analysis 
Variable OR p-value 95%CI OR p-value 95%CI 
Age 1.02 0.352 0.98-1.05    
Gender 0.23 0.022 0.07-0.81    
Family history of sudden death 0.23 0.022 0.07-0.81    
Left ventricular involvement 2.50 0.172 0.67-9.31    
VT on Holter 1.63 0.448 0.46-5.69    
Unexplained syncope 12.82 0.004 2.27-72.28 12.60 0.015 1.63-97.35 
VEQSI max (1ms increment) 1.09 0.001 1.04-1.15 1.09 0.001 1.03-1.15 
VEQSI max (5ms increment)    1.53 0.001 1.19-1.98 
VEQSI max (10ms increment)    2.35 0.001 1.41-3.92 
Constant    0.18 0.000 0.08-0.40 
 
OR, odds ratio; CI, confidence interval; VT, ventricular tachycardia; VEQSI, 
ventricular ectopic QRS interval 
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Figure Legends 
Figure 1 
Measurement of the ventricular ectopic QRS interval (VEQSI). Panel A 
demonstrates a narrow ventricular ectopic beat (VEB) from a healthy control 
(VEQSI 157ms). Panel B demonstrates a narrow right ventricular outflow tract 
VEB from a patient with a structurally normal heart (VEQSI 157ms). Panel C 
demonstrates a broad VEB from a patient with arrhythmogenic right ventricular 
cardiomyopathy (VEQSI 231ms). 
 
Figure 2 
The maximal ventricular ectopic QRS interval (VEQSI max) in normal controls, 
patients with definite and incompletely expressed arrhythmogenic right 
ventricular cardiomyopathy (ARVC) and patients with normal heart right 
ventricular outflow tract (RVOT) ectopy (raw data). 
 
Figure 3 
The ventricular ectopic QRS interval (VEQSI) in normal controls, patients with 
definite and incompletely expressed arrhythmogenic right ventricular 
cardiomyopathy (ARVC) and patients with normal heart right ventricular outflow 
tract (RVOT) ectopy according to ventricular ectopic beat (VEB) morphology (raw 
data).  
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